Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases.

BACKGROUND Aberrant expression of iron(II)- and 2-oxoglutarate-dependent JumonjiC histone demethylases has been linked to cancer. Potent demethylase inhibitors are drug candidates and biochemical tools to elucidate the functional impact of demethylase inhibition. METHODS & RESULTS Virtual screening identified a novel lead scaffold against JMJD2A with low-micromolar potency in vitro. Analogs were acquired from commercial sources respectively synthesized in feedback with biological testing. Optimized compounds were transformed into cell-permeable prodrugs. A cocrystal x-ray structure revealed the mode of binding of these compounds as competitive to 2-oxoglutarate and confirmed kinetic experiments. Selectivity studies revealed a preference for JMJD2A and JARID1A over JMJD3. CONCLUSION Virtual screening and rational structural optimization led to a novel scaffold for highly potent and selective JMJD2A inhibitors.

[1]  A. Link,et al.  Tetrazolylhydrazides as Selective Fragment‐Like Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A , 2015, ChemMedChem.

[2]  Helen Y Wang,et al.  JMJD3 as an epigenetic regulator in development and disease. , 2015, The international journal of biochemistry & cell biology.

[3]  C. Schofield,et al.  The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves. , 2015, Phytochemistry.

[4]  S. Knapp,et al.  Probing the epigenome. , 2015, Nature chemical biology.

[5]  P. Trojer,et al.  Targeting histone lysine methylation in cancer. , 2015, Pharmacology & therapeutics.

[6]  R. González-Barrios,et al.  The role of the histone demethylase KDM4A in cancer. , 2015, Cancer genetics.

[7]  W. Sippl,et al.  Discovery of Histone Demethylase Inhibitors , 2015 .

[8]  C. Schofield,et al.  Targeting histone lysine demethylases — Progress, challenges, and the future , 2014, Biochimica et biophysica acta.

[9]  K. Helin,et al.  Kruidenier et al. reply , 2014, Nature.

[10]  Kristian Helin,et al.  Inhibition of demethylases by GSK-J1/J4 , 2014, Nature.

[11]  P. Staller,et al.  The KDM5 family of histone demethylases as targets in oncology drug discovery. , 2014, Epigenomics.

[12]  U. Oppermann,et al.  The roles of Jumonji-type oxygenases in human disease , 2014, Epigenomics.

[13]  E. Novellino,et al.  Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. , 2014, Journal of medicinal chemistry.

[14]  Kristian Helin,et al.  Histone lysine demethylases as targets for anticancer therapy , 2013, Nature Reviews Drug Discovery.

[15]  Yusuke Nakamura,et al.  Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition. , 2013, Cancer letters.

[16]  W. Sippl,et al.  The role of histone demethylases in cancer therapy , 2012, Molecular oncology.

[17]  Frédérick A. Mallette,et al.  JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. , 2012, Cell reports.

[18]  S. Lightfoot,et al.  Oncogenic features of the JMJD2A histone demethylase in breast cancer. , 2012, International journal of oncology.

[19]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[20]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[21]  R. Janknecht,et al.  The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells , 2012, Journal of cellular biochemistry.

[22]  Sharon Y. R. Dent,et al.  Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. , 2012, Epigenomics.

[23]  L. Guyard,et al.  A more efficient synthesis of 4,4′,4′′-tricarboxy-2,2′:6′,2′′-terpyridine , 2011 .

[24]  W. Jiang,et al.  Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. , 2011, Anticancer research.

[25]  N. Mongan,et al.  Role of androgen receptor and associated lysine‐demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer , 2011, Molecular carcinogenesis.

[26]  Takayoshi Suzuki,et al.  Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.

[27]  L. Bird.  High throughput construction and small scale expression screening of multi-tag vectors in Escherichia coli. , 2011, Methods.

[28]  S. Schreiber,et al.  A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. , 2011, Journal of the American Chemical Society.

[29]  K. Helin,et al.  Inhibitors of histone demethylases. , 2011, Bioorganic & medicinal chemistry.

[30]  T. Heightman,et al.  Inhibition of Histone Demethylases by 4‐Carboxy‐2,2′‐Bipyridyl Compounds , 2011, ChemMedChem.

[31]  A. Jadhav,et al.  Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors , 2010, PloS one.

[32]  Makoto Hasegawa,et al.  Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. , 2010, Journal of medicinal chemistry.

[33]  C. Allis,et al.  Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.

[34]  René Meier,et al.  ParaDockS: A Framework for Molecular Docking with Population-Based Metaheuristics , 2010, J. Chem. Inf. Model..

[35]  G. Koten,et al.  Cyclometalated Organoruthenium Complexes for Application in Dye-Sensitized Solar Cells , 2010 .

[36]  Wolfgang Sippl,et al.  The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors , 2009, ChemMedChem.

[37]  S. Sainsbury,et al.  The structure of NMB1585, a MarR-family regulator from Neisseria meningitidis , 2009, Acta crystallographica. Section F, Structural biology and crystallization communications.

[38]  U. Oppermann,et al.  Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. , 2008, Journal of medicinal chemistry.

[39]  Isabelle Paquin,et al.  Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. , 2008, Journal of medicinal chemistry.

[40]  K. Al-Zaydi,et al.  Microwave assisted condensation reactions of 2-aryl hydrazonopropanals with nucleophilic reagents and dimethyl acetylenedicarboxylate. , 2007, Molecules.

[41]  R. Janknecht,et al.  Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. , 2007, Biochemical and biophysical research communications.

[42]  James E. Bray,et al.  Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity , 2007, Nature.

[43]  S. Berger.  The complex language of chromatin regulation during transcription , 2007, Nature.

[44]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[45]  David Alderton,et al.  A versatile ligation-independent cloning method suitable for high-throughput expression screening applications , 2007, Nucleic acids research.

[46]  H. Maag.  Prodrugs of Carboxylic Acids , 2007 .

[47]  Yi Zhang,et al.  JmjC-domain-containing proteins and histone demethylation , 2006, Nature Reviews Genetics.

[48]  Juri Rappsilber,et al.  The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3 , 2006, Nature.

[49]  Yang Shi,et al.  Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases , 2006, Cell.

[50]  H. Erdjument-Bromage,et al.  Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.

[51]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[52]  Antoine H. F. M. Peters,et al.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription , 2005, Nature.

[53]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[54]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[55]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[56]  C. Allis,et al.  Histone methylation versus histone acetylation: new insights into epigenetic regulation. , 2001, Current opinion in cell biology.

[57]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[58]  M. Bernatowicz,et al.  1H-Pyrazole-1-carboxamidine hydrochloride an attractive reagent for guanylation of amines and its application to peptide synthesis , 1992 .

[59]  M. Imamura,et al.  Characterization of 21 newly established esophageal cancer cell lines , 1992, Cancer.